Clinical trials
catalyst calendar across sponsors →Studies where GH is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 observational
Held by 21 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, BAILLIE GIFFORD & CO, JANE STREET GROUP, LLC, MILLENNIUM MANAGEMENT LLC, Artisan Partners Limited Partnership, +16 more) · FINRA short interest 5.4 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 30 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuationNCT05935384observationalSensitivity of ctDNA to Detect Disease Progression | — | Recruiting | Diagnostic test: Guardant360 | Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer | 470 | 2030-12-30 | in 1,594 d | 2025-08-22 |
| Shield Post-Approval Study ProtocolNCT06880055observationalPerformance measures of the Shield test will be assessed for the second testing interval | — | Recruiting | Diagnostic test: Shield Blood Test for colo-rectal cancer Screening | Colo-rectal Cancer | 3,375 | 2030-09-01 | in 1,474 d | 2026-08-07 |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationNCT05059444observationalDistant Recurrence Free Interval (D-RFi) | — | Recruiting | Diagnostic test: Guardant Reveal | Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma | 2,020 | Aug 2029 | ≤ 1,108 d | 2025-08-22 |
| Decision Counseling and Follow-up for Shield+ PatientsNCT07620535observationalCDE Decisional Conflict | — | Not yet recruiting | Behavioral: Decision Counseling Session | Colo-rectal Cancer | 350 | Dec 2027 | ≤ 499 d | 2026-06-02 |
| Screening for High Frequency Malignant DiseaseNCT05117840observationalPerformance characteristics of Guardant LUNAR-2 test | — | Active, not recruiting | Device: Low-dose CT scan | Lung Cancer | 12,000 | 2026-12-31 | in 134 d | 2026-07-06 |
| Evaluation of the ctDNA LUNAR Test in an Average Patient Screening EpisodeNCT04136002observationalSensitivity of colorectal cancer detection | — | Active, not recruiting | — | Colorectal Cancer | 44,467 | 2024-03-20actual | — | 2026-05-14 |
| Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast CancerNCT04436393observationalOverall Survival | — | Completed | Diagnostic test: Guardant360 test | Advanced Breast Cancer | 109 | 2022-03-17actual | — | 2022-06-22 |
| Noninvasive vs. Invasive Lung EvaluationNCT03615443observationalDemonstrate the non-inferiority of cfDNA-based vs. tumor tissue-based genotyping | — | Completed | Diagnostic test: Guardant360 | Non-Small Cell Lung Cancer | 306 | 2020-11-23actual | — | 2021-05-03 |
| Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical RecordsNCT03625557observationalObjective response rate (ORR) | — | Completed | — | Non-Hematologic Malignancy | 30 | 2020-02-01actual | — | 2020-04-17 |
| Registry of Guardant360® Use and Outcomes In People With Advanced CancerNCT03477474observationalEstimate Progression Free Survival (PFS) | — | Terminatedsponsor's stated reason: Alternative data published | — | Non-small Cell Lung Cancer Metastatic | 311 | 2019-09-01actual | — | 2019-10-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19